ALMS Fundamental Analysis - ALUMIS INC

Fundamental Rating

Overall ALMS gets a fundamental rating of 2 out of 10. We evaluated ALMS against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ALMS as it has an excellent financial health rating, but there are worries on the profitability. ALMS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALMS has reported negative net income.

In the past year ALMS has reported a negative cash flow from operations.

1.2 Ratios

With a Return On Assets value of -131.40%, ALMS is not doing good in the industry: 81.87% of the companies in the same industry are doing better.

The Return On Equity of ALMS (-203.99%) is worse than 68.39% of its industry peers.

		Industry Rank	Sector Rank
ROA	-131.4%
ROE	-203.99%
ROIC	N/A

ROA(3y)-120.91%

ROA(5y)N/A

ROE(3y)-222.13%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for ALMS has been increased compared to 1 year ago.

ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ALMS has an Altman-Z score of -4.46. This is a bad value and indicates that ALMS is not financially healthy and even has some risk of bankruptcy.

ALMS's Altman-Z score of -4.46 is in line compared to the rest of the industry. ALMS outperforms 43.01% of its industry peers.

There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.46

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.73 indicates that ALMS has no problem at all paying its short term obligations.

ALMS has a better Current ratio (3.73) than 62.69% of its industry peers.

ALMS has a Quick Ratio of 3.73. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 3.73, ALMS is doing good in the industry, outperforming 64.25% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.73
Quick Ratio	3.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.89%.

EPS 1Y (TTM)-80.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-89.62%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.31% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y47.45%

EPS Next 2Y26.43%

EPS Next 3Y16.31%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALMS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALMS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALMS's earnings are expected to grow with 16.31% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.43%

EPS Next 3Y16.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALMS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALUMIS INC

NASDAQ:ALMS (8/18/2025, 9:17:28 PM)

Premarket: 4.85 0 (0%)

4.85

+0.1 (+2.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-14 2025-05-14/amc

Earnings (Next)08-19 2025-08-19

Inst Owners20.22%

Inst Owner Change90.95%

Ins Owners0.64%

Ins Owner Change41.33%

Market Cap504.69M

Analysts87.14

Price Target20.84 (329.69%)

Short Float %4.58%

Short Ratio3.68

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)31.85%

Min EPS beat(2)-20.07%

Max EPS beat(2)83.78%

EPS beat(4)1

Avg EPS beat(4)-47.03%

Min EPS beat(4)-249.36%

Max EPS beat(4)83.78%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.83%

PT rev (3m)-4.98%

EPS NQ rev (1m)0.42%

EPS NQ rev (3m)-32.96%

EPS NY rev (1m)0%

EPS NY rev (3m)-16.86%

Revenue NQ rev (1m)42.86%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)2.65%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	29.02
P/FCF	N/A
P/OCF	N/A
P/B	3
P/tB	3
EV/EBITDA	N/A

EPS(TTM)-26.88

EYN/A

EPS(NY)-3.55

Fwd EYN/A

FCF(TTM)-2.81

FCFYN/A

OCF(TTM)-2.8

OCFYN/A

SpS0.17

BVpS1.62

TBVpS1.62

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-131.4%
ROE	-203.99%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-120.91%

ROA(5y)N/A

ROE(3y)-222.13%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.07

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	49.86%
Cap/Sales	9.28%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.73
Quick Ratio	3.73
Altman-Z	-4.46

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)455.91%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-80.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-89.62%

EPS Next Y47.45%

EPS Next 2Y26.43%

EPS Next 3Y16.31%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-90.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.81%

EBIT Next 3Y1.17%

EBIT Next 5YN/A

FCF growth 1Y-90.97%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-96.25%

OCF growth 3YN/A

OCF growth 5YN/A

ALUMIS INC (ALMS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens